## **COVID-19 infection and thrombotic disorders**

Since December 2019, a new type of pneumonia defined as coronavirus disease 2019 (COVID-19) is spreading worldwide and affecting an increasing number of people every day. Main symptoms are fever and cough, and most of patients recover spontaneously. However, about 1 in 6 patients can develop breathing difficulties and in some of them the disease progresses to a more systemic disease and multiple organ dysfunction (1). Patient's risk stratification is key to optimize COVID-19 patients flow at hospital. Stratification is currently based on characteristics of severe pneumonia and on laboratory findings.

Elevated D-dimer is now recognized to be associated with the severity of COVID-19 disease and is reported to be of poor prognosis (2). Table 1 shows D-dimer values in COVID-19 patients, from recent published papers; these observations notably show that markedly high D-dimer values are correlated with fatal outcome (2–5). Prolonged prothrombin time, decreased platelet count and lower fibrinogen levels are also commonly described in severe patients (2,3,6).

Altogether these findings would suggest that the development of active consumption coagulopathy, especially disseminated intravascular coagulation (DIC), is not rare in COVID-19 patients, and that its onset may unfavorably affect the clinical course.

Several international, national or local learning societies have issued recommendations for coagulopathy management in COVID-19 patients, such as ISTH (Internal Society of Thrombosis and Haemostasis), BSH (British Society of Haematology) or GFHT (French group for Haemostasis and Thrombosis)(7–11). All agree to recommend prophylactic anticoagulation, preferably with low molecular weight heparin (LMWH) provided patients do not suffer from severe renal impairment, even if dosage and patient's selection may vary slightly between guidelines (12,13). It should however be considered to monitor LMWH with anti-Xa activity when LMWH dosage is superior than prophylactic regimen, or in renal impairment patients (10). In addition, all recent recommendations agree that a screening coagulation panel including D-dimer, PT, platelet count and fibrinogen may be of help to identify prospectively severe COVID-19 patients. These parameters may be used alone or within clinical scores such as ISTH-DIC score or SIC score (8,12).

It is worth noting that many unknowns remain in this infection. Guidelines authors thus indicate that their statements will be modified regularly according to developing knowledge.

	Survivors (n = 162)	Non-survivors (n = 21)	p valu
Tang N et al.(2)	0.61 (0.35-1.29)	2.12 (0.77-5.27)	<0.00
	No ICU care (n=28)	ICU care (n=13)	
Huang C et al.(3)	0.5 (0.3–0.8)	2.4 (0.6–14.4)	0.004
	Survivors (n=137)	Non-survivors (n=54)	
Zhou F et al.(5)	0.6 (0.3–1.0)	5.2 (1.5–21.1)	<0.000

**Table 1.** D-dimer values from (2,3,5) in COVID-19 patients according to severity or clinical outcome.

## References

- 1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Feb 28;0(0):null.
- 2. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844–7.
- 3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020 Mar;395(10229):1054–62.
- 4. Han H, Yang L, Liu R, Liu F, Wu K, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med CCLM [Internet]. 2020 Mar 16 [cited 2020 Apr 5];0(0). Available from: http://www.degruyter.com/view/j/cclm.ahead-of-print/cclm-2020-0188/cclm-2020-0188.xml
- 5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020 Feb;395(10223):497–506.
- 6. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta Int J Clin Chem. 2020 Mar 13;506:145–8.
- 7. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost [Internet]. 2020 Mar 25 [cited 2020 Apr 5]; Available from: http://doi.wiley.com/10.1111/jth.14810
- 8. BSH Haemostasis and Thrombosis Task Force,. The DIC score is of prognostic value in COVID-19 pneumonia. 2020 Mar 18 [cited 2020 Apr 4]; Available from: https://b-s-h.org.uk/media/18151/dic-score-in-covid-19-pneumonia\_19-03-2020.pdf
- 9. Hunt B, Retter A, McClintock Cl. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. Thromb UK [Internet]. 2020 Mar [cited 2020 Apr 4]; Available from: https://thrombosisuk.org/covid-19-thrombosis.php
- 10. Susen S, Tacquard CA, Godon A. 'Traitement anticoagulant pour la prévention du risque thrombotique chez un patient hospitalisé avec Covid-19 et surveillance de l'hémostase. Proposition du GIHP et du GFHT.' [French]. [cited 2020 Apr 5]; Available from: https://site.geht.org/app/uploads/2020/04/COVID-19-GIHP-GFHT-3-avril-final.pdf
- 11. COVID-19 Protocols [Internet]. Brigham and Women's Hospital COVID-19 Clinical Guidelines. [cited 2020 Apr 5]. Available from: https://5e88df59aaaf821969eb430b--covid-protocols.netlify.com/protocols/protocol/

- 12. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost [Internet]. 2020 Mar 27 [cited 2020 Apr 5]; Available from: http://doi.wiley.com/10.1111/jth.14817
- 13. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost JTH. 2020 Apr 2;